Core Viewpoint - Shanghai Kelly Tai Medical Technology Co., Ltd. announced a correction regarding the sale of equity in Jianuo Medical Management Group Co., Ltd. and the reduction of capital to exit Shanghai Jingzheng Medical Technology Co., Ltd. [1] Financial Data Correction - The financial data for Jingzheng Medical for the most recent year and period has been corrected as follows: - Total assets as of December 31, 2024: 502.77 million (audited) and as of May 31, 2025: 531.57 million (unaudited) [2] - Total liabilities as of December 31, 2024: 302.51 million (audited) and as of May 31, 2025: 312.74 million (unaudited) [2] - Net assets as of December 31, 2024: 200.26 million (audited) and as of May 31, 2025: 218.83 million (unaudited) [2] - Total receivables as of December 31, 2024: 96.72 million (audited) and as of May 31, 2025: 94.77 million (unaudited) [2] Company Commitment - The company expressed its commitment to improving the quality of information disclosure and will enhance the verification process for future disclosures [2][3]

Core Viewpoint - The company, 今海医疗科技, is expected to report a tax loss of approximately 10.8 million Singapore dollars for the fiscal year ending June 30, 2025, and a tax loss of about 6 million Singapore dollars for the fiscal year ending June 30, 2024 [1] Financial Performance - The increase in net loss for the first half of 2025 is primarily attributed to a decrease in gross profit of around 5 million Singapore dollars [1] - The decline in revenue is linked to the company's minimally invasive surgical solutions, medical products and related services, and dormitory services [1]

Core Insights - The rapid adoption of the DeepSeek model in early 2025 has significantly boosted AI applications across various industries, particularly in healthcare, leading to a shift in computing demand from training to inference and fine-tuning [1] - Huawei's Ascend computing division is evolving its product and partnership ecosystem to meet the growing AI market demands, with a focus on customer engagement and tailored solutions [1][3] Industry Developments - The Ascend APN program was launched to foster collaboration with industry partners, aiming to build a robust AI ecosystem, particularly in healthcare, where significant advancements have been made in clinical decision support systems [3][4] - The APN program has attracted over 100 partners and developed more than 100 products since its inception, indicating strong industry interest and collaboration [4] Product Innovations - Huawei's Ascend series has expanded its product offerings, including the introduction of 70T and 100T computing capabilities to cater to low-power scenarios, with a range of computing power from 8T to 560T [6][8] - The launch of the intelligent monitoring system by Turing Medical demonstrates the practical application of Ascend's edge computing capabilities in real-time patient monitoring [9] Ecosystem Expansion - The open-sourcing of CANN, Huawei's neural network computing architecture, is expected to attract more partners and enhance the Ascend ecosystem, facilitating easier integration of AI applications across various sectors [10][11] - Huawei's commitment to an open ecosystem aims to simplify the use of CANN and Ascend products in diverse industries, ensuring that AI applications can effectively meet the computational demands of various scenarios [11]

Core Insights - The "Optics Valley" initiative has gained consensus among young talents aspiring for innovation and entrepreneurship, providing comprehensive support in funding, technology, space, and public services to attract around 2 million young talents, with over 70% being under 35 years old [1] - The Hubei Youth Innovation Park (Optics Valley Youth Innovation Park) has gathered 254 hard-tech companies, focusing on a structured growth path for enterprises, including incubation, acceleration, and tailored services [2] - The Wuhan Industrial Innovation Development Research Institute (WII) aims to stimulate innovation and entrepreneurship among young talents by establishing a supportive incubation system and facilitating connections with industry resources [3] Group 1 - The Optics Valley Youth Innovation Park has provided over 2,000 precise services to incubated enterprises, helping them secure over 200 million yuan in financing and loans, and has successfully graduated 58 enterprises [2] - The park's layout includes incubation spaces on floors 5-6, incubator areas on floors 7-8, and accelerator zones on floors 9-14, functioning as a technology transfer hub rather than a traditional incubator [2] - The park's focus is on fostering hard-tech enterprises and creating job opportunities for youth, having already facilitated employment for over 2,500 individuals [2] Group 2 - The WII has established over 90 innovation units, including research institutes and public service platforms, and has incubated over 900 technology achievements and 400 technology companies within three years [3] - The WII collaborates with universities and medical institutions to create joint laboratories and talent training bases, enhancing the integration of AI algorithms with local healthcare needs [3] - The integration of educational and technological resources in Wuhan is seen as a key factor in promoting collaborative innovation and achieving a multiplier effect in research and development [4] Group 3 - Continuous policy innovation is essential to address the challenges faced by young entrepreneurs, with an emphasis on optimizing institutional support [5] - The focus is on bridging the gap between university research outcomes and enterprise needs, while also concentrating resources to build strategic technological capabilities [5] - A market-oriented and human-centered approach is advocated to enhance talent retention and convert talent advantages into developmental benefits [5]

Core Insights - The "Optics Valley" has become a hub for young talent in innovation and entrepreneurship, attracting around 2 million young individuals, with over 70% being under 35 years old [1][5][6] - The "Optics Valley Youth Innovation Park" has gathered 254 hard-tech companies, providing comprehensive support including funding, technology, and public services [5][6] - The park has facilitated over 2 billion yuan in financing and loans for startups, helping to create more than 2,500 jobs [6][8] Group 1: Innovation Ecosystem - The park is designed as a "tropical rainforest" style innovation ecosystem, fostering collaboration between universities, research institutions, and enterprises [7][8] - The park's structure includes incubation spaces and acceleration zones, tailored to the growth stages of startups [5][6] - The establishment of the Wuhan Industrial Innovation Development Research Institute aims to support projects with high technical maturity and connect them with industry resources [6][7] Group 2: Success Stories - Companies like QianDa Intelligent have successfully secured angel funding for technology iteration and market expansion, breaking foreign technology monopolies [5][6] - The founder of JingZhen Technology, a Tsinghua University PhD, has established partnerships with medical institutions to integrate AI with healthcare [7] - The Wuhan Industrial Innovation Development Research Institute has incubated over 900 technology achievements and 400 tech companies within three years [7][8] Group 3: Policy and Future Directions - Continuous policy innovation is essential to address challenges faced by young entrepreneurs and optimize institutional support [8] - Emphasis on deep integration of industry, academia, and research to bridge the gap between university outputs and enterprise needs [8] - A focus on providing comprehensive support for talent throughout their career lifecycle to enhance retention and development advantages [8]

Group 1 - The stock of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. (stock code: 301363) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days (August 21, 2025, August 22, 2025, and August 25, 2025) [1] - The company's board of directors verified the situation with the controlling shareholder and actual controller, confirming that there are no undisclosed significant information that could impact the stock price [1] - The board confirmed that there are no matters that should have been disclosed according to the Shenzhen Stock Exchange's rules that have not been disclosed, nor any significant matters in the planning stage that require disclosure [1]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第三届董事会第 二次会议于 2025 年 8 月 25 日上午在上海市虹漕路 456 号光启大楼 20 楼公司董 事会议室/北京市朝阳区东三环北路 19 号嘉盛中心 1810 室以现场与视讯相结合 的方式召开。会议通知于 2025 年 8 月 15 日以电子邮件方式发出。本次会议由董 事长李惇先生主持，应到董事 6 人，实到董事 6 人。部分高级管理人员列席了会 议。会议的召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合 法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《2025 年半年度报告》及《2025 年半年度报告摘要》。 合富（中国）医疗科技股份有限公司 在提交本次董事会审议前，该议 ...

Group 1 - The core viewpoint of the news is that Madi Technology (603990) has shown a mixed performance in its latest financial results, with a significant drop in revenue but a notable increase in net profit [1] - As of August 25, 2025, Madi Technology's stock closed at 15.36 yuan, with a slight increase of 0.26% and a trading volume of 178,400 hands, amounting to 273 million yuan [1] - The company experienced a net outflow of main funds amounting to 25.92 million yuan, which represents 9.49% of the total transaction amount, indicating a cautious sentiment among investors [1] Group 2 - For the latest financial period ending in mid-2025, Madi Technology reported total operating revenue of 135 million yuan, a decrease of 47.24% year-on-year, while net profit attributable to shareholders was 28.33 million yuan, an increase of 137.11% [1] - The company has a current ratio of 2.509, a quick ratio of 2.388, and a debt-to-asset ratio of 33.30%, indicating a strong liquidity position [1] - Madi Technology, established in 2009 and located in Suzhou, has a registered capital of 3.06 billion yuan and has made investments in 9 companies, participated in 3,041 bidding projects, and holds 84 trademarks and 169 patents [2]

Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures, initially debuting in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to expand the market coverage of existing equipment systems, thereby increasing procurement and usage rates [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈推出PixelPeel™安全激光煥膚治療方案（「該方案」），旨在滿足對 安全、有效且恢復期短的皮膚煥新療程日益增長的需求，並全面運用在新一代 Alma Pixel™及Alma Hybrid設備系統中。該方案已於北美首發，並計劃逐步推向 全球市場。 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香 生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 PixelPeel™運用臨床公認的黃金標準激光能量，結合像素級精準度，並搭載Alma 專利MotionSync™技術，確保治療過程安全、 ...